» Articles » PMID: 27187358

The Growing Complexity of Cancer Cell Response to DNA-Damaging Agents: Caspase 3 Mediates Cell Death or Survival?

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2016 May 18
PMID 27187358
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

It is widely stated that wild-type p53 either mediates the activation of cell cycle checkpoints to facilitate DNA repair and promote cell survival, or orchestrates apoptotic cell death following exposure to cancer therapeutic agents. This reigning paradigm has been challenged by numerous discoveries with different human cell types, including solid tumor-derived cell lines. Thus, activation of the p53 signaling pathway by ionizing radiation and other DNA-damaging agents hinders apoptosis and triggers growth arrest (e.g., through premature senescence) in some genetic backgrounds; such growth arrested cells remain viable, secrete growth-promoting factors, and give rise to progeny with stem cell-like properties. In addition, caspase 3, which is best known for its role in the execution phase of apoptosis, has been recently reported to facilitate (rather than suppress) DNA damage-induced genomic instability and carcinogenesis. This observation is consistent with an earlier report demonstrating that caspase 3 mediates secretion of the pro-survival factor prostaglandin E₂, which in turn promotes enrichment of tumor repopulating cells. In this article, we review these and related discoveries and point out novel cancer therapeutic strategies. One of our objectives is to demonstrate the growing complexity of the DNA damage response beyond the conventional "repair and survive, or die" hypothesis.

Citing Articles

Discovery of Potent Isoquinolinequinone -Oxides to Overcome Cancer Multidrug Resistance.

Kruschel R, Barbosa M, Almeida M, Xavier C, Vasconcelos M, McCarthy F J Med Chem. 2024; 67(16):13909-13924.

PMID: 39093920 PMC: 11345829. DOI: 10.1021/acs.jmedchem.4c00705.


Changing the Landscape of Solid Tumor Therapy from Apoptosis-Promoting to Apoptosis-Inhibiting Strategies.

Mirzayans R Curr Issues Mol Biol. 2024; 46(6):5379-5396.

PMID: 38920994 PMC: 11202608. DOI: 10.3390/cimb46060322.


Intratumor Heterogeneity and Treatment Resistance of Solid Tumors with a Focus on Polyploid/Senescent Giant Cancer Cells (PGCCs).

Mirzayans R, Murray D Int J Mol Sci. 2023; 24(14).

PMID: 37511291 PMC: 10380821. DOI: 10.3390/ijms241411534.


New triorganotin(iv) compounds with aromatic carboxylate ligands: synthesis and evaluation of the pro-apoptotic mechanism.

Rashid F, Uddin N, Ali S, Haider A, Tirmizi S, Diaconescu P RSC Adv. 2022; 11(8):4499-4514.

PMID: 35424423 PMC: 8694426. DOI: 10.1039/d0ra06695h.


Inhibition of PI3K and MAPK pathways along with KIT inhibitors as a strategy to overcome drug resistance in gastrointestinal stromal tumors.

Gupta A, Ma S, Che K, Pobbati A, Rubin B PLoS One. 2021; 16(7):e0252689.

PMID: 34324512 PMC: 8320897. DOI: 10.1371/journal.pone.0252689.


References
1.
Mirzayans R, Andrais B, Scott A, Paterson M, Murray D . Single-cell analysis of p16(INK4a) and p21(WAF1) expression suggests distinct mechanisms of senescence in normal human and Li-Fraumeni Syndrome fibroblasts. J Cell Physiol. 2009; 223(1):57-67. DOI: 10.1002/jcp.22002. View

2.
Chang B, Broude E, Dokmanovic M, Zhu H, Ruth A, Xuan Y . A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res. 1999; 59(15):3761-7. View

3.
Zitvogel L, Kroemer G . Subversion of anticancer immunosurveillance by radiotherapy. Nat Immunol. 2015; 16(10):1005-7. DOI: 10.1038/ni.3236. View

4.
DAmelio M, Sheng M, Cecconi F . Caspase-3 in the central nervous system: beyond apoptosis. Trends Neurosci. 2012; 35(11):700-9. DOI: 10.1016/j.tins.2012.06.004. View

5.
Takahashi M, Koi M, Balaguer F, Boland C, Goel A . MSH3 mediates sensitization of colorectal cancer cells to cisplatin, oxaliplatin, and a poly(ADP-ribose) polymerase inhibitor. J Biol Chem. 2011; 286(14):12157-65. PMC: 3069420. DOI: 10.1074/jbc.M110.198804. View